Twist Bioscience Corporation (TWST) Tops Q1 EPS by 2c, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Twist Bioscience Corporation (TWST) Tops Q1 EPS by 2c, Revenues Beat; Offers FY21 Revenue Mid-Point Guidance Below Consensus

Twist Bioscience Reports First Quarter Fiscal 2021 Financial Results

February 4, 2021 4:05 PM EST

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31, 2020.

We reported a strong quarter both for orders and revenue, building a solid foundation for fiscal 2021, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. We see early evidence that our investment in synbio products for our pharmaceutical and biotech customers is beginning to gain... More